ENvue Medical’s ENvue business generated approximately $184,000 of Q2 2026 revenue, up 275% from $49,000, as expansion of its installed hospital base and growing adoption of the ENvue Navigation Platform partially offset a major production interruption in the company’s legacy PainShield and UroShield businesses.
Despite ENvue’s growth, consolidated quarterly revenue fell 51.6% to approximately $239,000 from $494,000 because production of PainShield and UroShield was halted as operations were moved from Israel to the United States amid the regional conflict.
That manufacturing transition was completed in August, and production has now been re-established in the United States. The resumption creates the possibility that future consolidated results can combine renewed NanoVibronix product availability with continued ENvue hospital adoption.
For the first half, ENvue revenue increased approximately 100% to $303,000 from $152,000. The company renewed three-year purchasing agreements with two group purchasing organizations collectively representing more than 100 U.S. hospitals and secured a network-wide standardization agreement with a 12-hospital health system in Virginia and North Carolina.
Clinical evidence is also being used to support adoption. A peer-reviewed study published in June reported zero pulmonary misplacements across 531 procedures using the ENvue Navigation Platform and a 67% reduction in ventilator-associated pneumonia.
The company’s financial profile remains difficult. Q2 operating loss increased to approximately $5.47 million from $3.98 million, while net loss widened to approximately $4.90 million from $3.97 million.
Cash and equivalents declined to approximately $1.08 million at June 30 from $4.22 million at the end of 2025. ENvue Medical used approximately $7 million of operating cash during the first half and disclosed substantial doubt about its ability to continue as a going concern without additional capital.
The 275% increase in ENvue revenue consequently stands out within a quarter dominated by the temporary shutdown of the company’s legacy manufacturing operation, providing an early indication of how hospital adoption could alter the company’s revenue mix as PainShield and UroShield production resumes.
